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Sepsis and meningitis caused by Neisseria meningitidis serogroup B (NMGB) are serious diseases in infants
and young adults, but no effective vaccine is available. The capsular polysaccharide (PS) of NMGB has poor
immunogenicity and a structural similarity to polysialic acid (PSA) on neuronal tissue that may elicit
autoantibodies. Using HmenB3, a protective and nonautoreactive monoclonal antibody (MAb) to NMGB
capsular PS, we produced an anti-idiotypic MAb, Naid60, which mimics the capsular PS of NMGB. We
produced an anti-anti-idiotypic MAb, MoB34, by using the immunogenic site on Naid60 responsible for
inducing the anti-NMGB PS antibody response. MoB34 elicited the complement-mediated killing of represen-
tative strains of serogroup B meningococci. MoB34 did not bind to CHP-134, a neuroblastoma cell line
expressing (2-8) PSA, or to mouse brain cryosections at a high concentration. Naid60-keyhole limpet
hemocyanin immunization inhibited the growth of live NMGB in intraperitoneally challenged mice; in con-
trast, three of five control mice developed bacteremia. Thus, Naid60 has an immunogenic site that elicits
antibodies with bactericidal activity against NMGB and no autoimmunity to PSA. We suggest that the
immunogenic region of Naid60 is a candidate for the development of a new vaccine against NMGB.
Neisseria meningitidis is a gram-negative encapsulated bac-
terium and is the most common cause of bacterial meningitis.
N. meningitidis can be divided into 13 serogroups on the basis
of the structures of their capsular polysaccharides (PSs), which
are chemically and immunologically distinct in each group (11,
21, 41). Moreover, the five serogroups A, B, C, Y, and W135
account for the major meningococcal disease-causing isolates
in humans. The capsular PSs of N. meningitidis are important
determinants of virulence, and the presence of serum antibody
to capsular PS protects against disease. A meningococcal vac-
cine that uses capsular PSs from N. meningitidis serogroups A,
C, Y, and W135 is currently licensed; however, no meningo-
coccal vaccines are available to protect against meningococcal
diseases caused by N. meningitidis serogroup B (NMGB). The
lack of protection against NMGB in a meningococcal vaccine
is a serious problem because NMGB may account for about
50% of all meningococcal meningitis infections in Europe and
North America (32, 37, 40).
To produce an effective vaccine against NMGB, various
approaches have been studied by targeting new bacterial pro-
teins (9, 17, 29), after whole-genome sequencing of NMGB
(45), and lipopolysaccharide (LPS) (36) in addition to outer
membrane vesicle (4, 43) or N-propionylated PS (5). However,
the use of bacterial proteins is problematic in a vaccine be-
cause of significant serologic heterogeneity among different
strains of N. meningitidis serogroup B (1). With respect to the
capsular PS candidate, NMGB PS is an autoantigen that may
elicit autoantibodies that bind both NMGB and neuronal tis-
sue (13, 14, 31), because NMGB PS expresses a linear (2-8)
polymer of sialic acid; thus, NMGB PS has poor immunoge-
nicity due to immune tolerance. The structural modification of
capsular PS by the substitution of N-propionyl for N-acetyl
groups proved to be highly immunogenic (15) but showed the
possibility of eliciting autoantibodies (2, 16, 19). In a fine-
structure analysis of NMGB PS using MAbs, an immunogenic
epitope was found which elicits antibodies that activate com-
plement-mediated bacteriolysis and which has no autoantibody
activity (16, 42). Thus, this epitope may be a target for molec-
ular mimetics, such as peptide mimicry, for eliciting protective
antibody without inducing autoimmunity.
Peptide mimicry approaches have been demonstrated with
phage display technology for the PS of group B streptococcus
type III (35), Cryptococcus neoformans (46, 50), and serogroups
A and B of N. meningitidis (7, 8, 18, 42). Another approach to
peptide mimicry is offered by anti-idiotypic antibody, and the
feasibility of this approach has been demonstrated by an eval-
uation of peptide mimics of group B streptococcal infection
(26) and serogroup C (48) and recently serogroup B (3) N.
meningitidis, using a recombinant anti-idiotypic single-chain
variable fragment (scFv) methodology. Previously we reported
a MAb to NMGB PS, HmenB3, which has complement-medi-
ated bactericidal activity against NMGB but no autoimmunity
(42).
We now report on a monoclonal anti-idiotypic antibody to
HmenB3, Naid60, which has an immunogenic and protective
epitope that elicits antibodies to kill NMGB. We demonstrated
that Naid60 has no cross-reactive epitope with neuronal cell
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adhesion molecules (NCAMs) by using both Naid60 immune
sera and anti-anti-idiotypic MAb MoB34. Our experiments
show that the anti-idiotype approach offers a means of devel-
oping a vaccine for NMGB.
MATERIALS AND METHODS
Bacterial strains and polysaccharide. The NMGB strains used were ATCC
13090 (M2092) and H44/76 (B:15:P1.7,16). Bacteria were cultured on chocolate
agar plates at 37°C in a candle jar and harvested after 6 h. All bacteria were
aliquoted in Hanks’ balanced salt solution (HBSS) containing 20% glycerol at
70°C. Purified capsular PS of Escherichia coli K1 containing (2-8)-linked
polysialic acid (PSA), which is antigenically and structurally identical to the
capsular PS of NMGB (22), was a gift from W. Vann (Center for Biologics
Evaluation and Research, Food and Drug Administration).
Preparation of F(ab)2. HmenB3 {immunoglobulin M() [IgM()]} is a
mouse MAb specific for NMGB PS that kills 50% of NMGB at a concentration
of 1 ng/ml in the presence of rabbit complement and shows no binding to
CHP-134, a human neuroblastoma cell line expressing PSA, or to mouse brain
cryosections at a concentration of 25 g/ml (42). HmenB3 was purified from the
ascitic fluid of mice by Sephacryl S300 HR size-exclusion column chromatogra-
phy (Amersham Pharmacia Biotech, Piscataway, New Jersey), and F(ab)2 of
HmenB3 was prepared by low-temperature pepsin proteolysis (34). Briefly,
HmenB3 was dialyzed in sodium acetate buffer (0.02 M sodium acetate, 0.15 M
NaCl, pH 4.0) and digested with pepsin (Sigma Chemical Co., St. Louis, MO) at
an enzyme/antibody ratio of 1:1 (wt/wt) for 24 h at 4°C. The same amount of
pepsin was then added to continue the reaction for another 24 h. The digestion
mixture was slowly titrated back to neutrality with 2 M Tris solution. The mixture
was then dialyzed against phosphate-buffered saline (PBS), and a small amount
of denatured and/or aggregated material was removed by centrifugation.
F(ab)2 was purified by Sephacryl S300 HR gel filtration and confirmed by
nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 7.5%
gels. F(ab)2 fragments were coupled with keyhole limpet hemocyanin (KLH)
or bovine serum albumin (28) for use as an immunogen for the production of
anti-idiotype MAb. Briefly, the same amounts of F(ab)2 fragments and carrier
protein were mixed, an equal volume of 0.2% glutaraldehyde in PBS was added
to the mixture with constant agitation, and the mixture was then incubated at
room temperature (RT) for 1 h. To stop the reaction, 1 M glycine was added to
a final concentration of 200 mM and incubated with stirring for 1 h. Finally the
reaction mixture was dialyzed with PBS and used for immunization.
Naid60 [IgG1()] is an anti-idiotype MAb to HmenB3, as described below.
F(ab)2 of Naid60 was prepared by pepsin proteolysis as described above. Naid60
was digested with pepsin at an enzyme/antibody ratio of 1:20 for 8 h at 37°C, and
the reaction was stopped by adding 2 M Tris solution. F(ab)2 fragments were
purified using a Superdex-75 gel filtration column (Amersham Pharmacia Bio-
tech). F(ab)2 fragments of Naid60 were coupled with carrier protein as de-
scribed above.
Production of anti-idiotypic MAb (Ab2) and anti-anti-idiotypic MAb (Ab3).
BALB/c mice were immunized intraperitoneally (i.p.) with 100 g of KLH-
conjugated F(ab)2 fragments of HmenB3 emulsified in complete Freund’s
adjuvant (CFA) and boosted twice with incomplete Freund’s adjuvant (IFA) at
2-week intervals. Finally, mice were injected intravenously with intact HmenB3
3 days before the fusion. Splenocytes were fused with P3-X63-Ag8.653 and
selected with hypoxanthine-aminopterin-thymidine medium. The resulting hy-
bridoma supernatants were screened by enzyme-linked immunosorbent assay
(ELISA), as described below, using ELISA plates coated with F(ab)2 frag-
ments of HmenB3. The binding specificity of the anti-idiotypic MAb to HmenB3
was tested by an inhibition ELISA with NMGB as a coating antigen. An anti-
idiotypic MAb was produced and named Naid60. The isotype of MAb was
determined using a mouse-hybridoma subtyping kit (Roche Diagnostics GmbH,
Mannheim, Germany) containing horseradish peroxidase (HRP)-conjugated
goat anti-mouse isotype-specific antibodies.
To generate an anti-anti-idiotypic MAb, KLH-conjugated F(ab)2 fragment of
Naid60 was used as an immunogen. The hybridoma supernatants producing Abs
were screened on plates coated with killed NMGB, and a hybridoma producing
an anti-anti-idiotypic MAb, named MoB34 [IgM()], was produced. The bacte-
ricidal activity of MoB34 was tested, and a bactericidal inhibition assay was
conducted to determine binding specificity, as described below.
ELISA and inhibition ELISA. Microtiter plates (Corning Inc., Corning, New
York) were coated with 10 g/ml of F(ab)2 of HmenB3 for anti-idiotypic MAb
screening. The plates were then washed with 0.05% Tween 20 in PBS (PBST)
and blocked with 5% normal goat serum in PBST. Hybridoma culture superna-
tants were added to the plates and incubated for 1.5 h at 37°C. After washing,
HRP-labeled goat anti-mouse IgG (Sigma) was added. After 1.5 h of incubation,
o-phenylenediamine was added to the plates and optical densities were measured
at 490 nm.
For anti-anti-idiotypic MAb screening, microtiter plates were coated with 10
g/ml of E. coli K1 PS or heat-inactivated NMGB bacteria. For NMGB coating,
NMGB (ATCC 13090) was killed at 65°C for 1 h and washed with PBS. One
hundred microliters of PBS containing NMGB (OD at 620 nm, 0.09) was added
to each well, and then the wells were dried at 37°C (18). HRP-labeled goat
anti-mouse Ig was used as a secondary antibody for the screening.
Inhibition ELISA was performed to confirm whether the anti-idiotope of
Naid60 has a structure similar to that of the NMGB PS epitope bound by
HmenB3. On the microtiter plates coated with NMGB, a constant amount of
HmenB3 was added to the wells in the presence of various concentrations of
purified Naid60. After incubation for 3 h at RT with gentle agitation, the plates
were washed and HRP-conjugated goat anti-mouse IgM (Sigma) was added to
the wells. After washing, color was developed and OD measured.
Surface plasmon resonance (BIAcore). Analysis of Naid60 binding to HmenB3
was also carried out using the BIAcore 3000 instrument (BIAcore AB, Uppsala,
Sweden). The running buffer used for sample dilution and analysis was HBS
buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween 20, pH
7.4). The research grade CM5 dextran sensor chip was activated with equal
amounts of 0.2 M N-ethyl-N-(3-diethylamino-propyl)-carbodiimide and 0.05 M
N-hydroxysuccinimide. HmenB3 at a concentration of 50 g/ml was immobilized
in 10 mM sodium acetate buffer (pH 4.0) followed by 1 M ethanolamine hydro-
chloride (pH 8.0) to deactivate excess N-hydroxysuccinimide esters. This cou-
pling resulted in 12,000 response units of immobilized antibodies per flow cell,
corresponding to approximately 10 ng protein/mm2. For the evaluation of bind-
ing, Naid60 was diluted in HBS buffer and analyzed at various concentrations.
Naid60 solution was passed over the sensor chip at a flow rate of 10 l/min.
HmenB5 (18), which is another anti-NMGB PS MAb cross-reactive with
NCAMs, was immobilized on the adjacent vacant flow cell under the same
conditions as a control antibody. An activated and blocked flow cell without
immobilized ligand was used to evaluate nonspecific binding. For all samples,
response curves were also recorded on control surfaces. Results were calculated
after subtraction of the control values, using the BIAevaluation 3.0 software
(BIAcore AB).
Complement-mediated bactericidal assay. The bactericidal assay was per-
formed in 96-well microtiter plates (42). Briefly, a 100-l mixture consisting of 30
l of N. meningitidis bacterial suspension (containing 2,500 CFU), 50 l of
diluted antibiotic-free Ab, and 20 l of baby rabbit complement was incubated at
37°C for 1 h. The concentration of rabbit serum was 2% for H44/76 and 10% for
ATCC 13090, depending on the susceptibility of the bacteria to the complement,
and an isotype-matched irrelevant MAb was used as a negative control. After
incubation, 10 l of the reaction mixture was cultured on a chocolate agar plate
to determine colony numbers. Two different strains of NMGB (ATCC 13090 and
H44/76) were used to avoid killing bacteria by binding bacterial surface antigens
other than capsular PS. Each assay was performed at least twice in triplicate, and
means were used to calculate percent killing with the formula [(CFU without
antibody  CFU of sample)/CFU without antibody]  100. For bactericidal
inhibition assay, a 100-l mixture consisting of 30 l of N. meningitidis bacterial
suspension, 25 l of diluted antibiotic-free Ab, 25 l of various concentrations of
inhibitor, and 20 l of baby rabbit complement was incubated at 37°C for 1 h.
Each assay was performed as described above.
Production of anti-idiotypic scFv antibody (Naid60-scFv). The heavy- and
light-chain variable regions from the Naid60 hybridoma were cloned into
pCANTAB5E vector (Amersham Pharmacia Biotech). The ligation mixture was
transformed into E. coli TG1 cells, and the phages were rescued with helper
phage M13KO7. The phage stock was prepared and phage selection was done by
one round of panning on plates coated with HmenB3. Recombinant phages
giving a positive ELISA signal on HmenB3-coated wells were used to produce
soluble scFv antibodies. For the production of soluble scFv antibodies, the scFv
gene was excised from the phage clone and inserted into the pRSET SfiI/NotI
expression vector (49). Affinity-purified Naid-scFv antibodies were obtained by
coexpressing the ligation mixture and pGroES/L plasmid as chaperonin (12) in E.
coli BL21(DE3).
Flow cytometric analysis. To test whether MoB34 binds to the PSA portion of
NCAMs, CHP-134 cells (24) were stained with MoB34 for flow cytometry.
CHP-134 cells were mixed with MoB34 at a high concentration of 100 g/ml and
incubated for 30 min on ice. After washing, the cells were incubated with fluo-
rescein isothiocyanate-conjugated goat anti-mouse Ig (BD Immunocytometry
Systems, San Jose, CA) for 1 h at RT. After another washing, the cells were
resuspended in 400 l of PBS containing 0.25% formaldehyde. Anti-CD56
6400 PARK ET AL. INFECT. IMMUN.
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(PharMingen, San Diego, CA), which is specific for NCAMs, and isotype-
matched irrelevant mouse MAb were used as positive and negative controls,
respectively. HmenB1, which is a mouse MAb to NMGB PS and which is known
to bind to CHP-134 cells (42), was also used at a concentration of 10 g/ml as a
positive control. Fluorescence was measured with a FACScaliber (Becton Dick-
inson, Mountain View, CA).
Histochemistry. The staining was performed with brains obtained from 1- to
2-week-old C57BL/6 mice. Five-micrometer-thick cryosections of brain were
incubated with MoB34 at concentrations of 50 and 100 g/ml for 75 min at RT,
washed with PBS, and incubated with biotin-conjugated goat anti-mouse IgM
antibody (Dako, Glostrup, Denmark) for 30 min. The slides were rewashed with
PBS and incubated with streptavidin-peroxidase (Dako) for 30 min. After this
washing, the slide was developed with a peroxidase substrate, 3-amino-9-ethyl-
carbazole (Dako), and counterstained with hematoxylin-eosin stain. HmenB1
was used as a positive control (42) at a concentration of 0.1 or 1 g/ml, and
isotype-matched irrelevant mouse MAb of anti-LPS Ab (Sigma) was used at a
concentration of 50 and 100 g/ml as a negative control.
Production of anti-NMGB antibody after immunization of mice with Naid60.
To test the generation of anti-anti-idiotypic MAb reactive to NMGB, we injected
BALB/c mice with Naid60-KLH. Female BALB/c mice 6 to 8 weeks old were i.p.
injected with 100 g of Naid60-KLH. The first injection was with CFA, and
boosting was with IFA at 2-week intervals. Serum samples were collected 7 days
after each injection. Serum Ab titers to NMGB were measured on NMGB-
coated microtiter plates. Serum samples were 1:100 diluted with 5% normal goat
serum–PBST and incubated for 1.5 h at 37°C. After washing, HRP-labeled goat
anti-mouse Ig (Sigma) and o-phenylenediamine were used for color develop-
ment.
Challenge experiments with live bacteria. BALB/c mice were subcutaneously
immunized with 100 g of Naid60-KLH with alum (Pierce, Rockford, IL) and 10
g of CpG oligodeonucleotides and boosted 4 more times at 2-week intervals.
We used alum to avoid adverse effects such as possible granulomas and abscesses
cause by Freund’s adjuvant. KLH-injected mice were used as a control. All mice
were rendered leukopenic by three i.p. injections of a dose of 200 mg/kg cyclo-
phosphamide on days 0, 2, and 4 to enhance their susceptibility to meningococcal
infection (10, 39). Finally, a dose of 100 mg/kg cyclophosphamide was given 2 h
before the bacterial challenge. Mice were then i.p. injected with 1  106 CFU
NMGB ATCC 13090, which had been passaged three times in neutropenic mice
for virulence (47). Blood specimens were obtained from the retro-orbital plexus,
and 10 l of each blood sample undiluted or diluted with HBSS at 1:10 and 1:100
was cultured on chocolate agar plates at 37°C. CFU were determined in dupli-
cate after 18 h of incubation in a candle jar.
Nucleotide sequence accession numbers. The sequences of the V regions of
Naid60 have been deposited in GenBank under accession numbers AY661813
for VH and AY661814 for VL.
RESULTS
Characterization of the anti-idiotypic MAb of Naid60. From
BALB/c mice immunized with KLH-F(ab)2 of HmenB3
emulsified with Freund’s adjuvant, we obtained one clone of a
hybridoma, Naid60, that reacted with both whole Ab and
F(ab)2 of HmenB3 by ELISA (data not shown). To test
whether Naid60 MAbs recognize the idiotope of HmenB3, we
examined the inhibition of HmenB3 binding to wells coated
with NMGB by adding various amounts of purified Naid60 as
a competitor. As shown in Fig. 1, Naid60 inhibited the binding
of HmenB3 to NMGB-coated microtiter plates in a dose-de-
pendent manner, like native antigen, E. coli K1 PS, which is
FIG. 1. Characterization of the anti-idiotype Ab of Naid60. Naid60
inhibited the binding of HmenB3 to wells coated with heat-killed
NMGB in a dose-dependent manner, like E. coli K1 PS, which is
structurally and antigenically identical to NMGB PS. Naid59, which
bound to HmenB3 but did not inhibit the binding of HmenB3 to
NMGB, was used as a negative control Ab.
FIG. 2. Surface plasmon resonance analysis of Naid60 binding to
immobilized HmenB3. The data represent five injections of Naid60 at
concentrations of 50, 25, 12.5, 6.25, and 3.13 nM from top to bottom (B
and D). HmenB5, which is an anti-NMGB PS MAb cross-reactive with
NCAM, was used for the control antibody (D). NMGB PS was used as
a positive control ligand to both HmenB3 and HmenB5, and the
bindings were demonstrated at concentrations of 5, 4, 3, and 2 mg/ml
of NMGB PS (A and C).
FIG. 3. Bactericidal inhibition of HmenB3 to NMGB by Naid60.
NMGB bacteria were incubated with HmenB3 and various amounts of
Naid60 in the presence of baby rabbit complement. Bactericidal inhi-
bitions were 36.9%, 92.6%, and 98.0% at 4, 40, and 400 g/ml of
Naid60, respectively, and 38.3% at 40 g/ml of E. coli K1 PS, a positive
control inhibitor.
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structurally and antigenically identical to NMGB PS (22). In
contrast, an irrelevant isotype control antibody failed to inhibit
the binding of HmenB3 to NMGB even at 100 g/ml. We
determined the V regions of Naid60.
Surface plasmon resonance analyses. We further estab-
lished the ability of the BIAcore to confirm the binding spec-
ificity of Naid60 to HmenB3. As shown in Fig. 2, the senso-
grams represent real-time binding of Naid60 to HmenB3 at
various concentrations of Naid60. Naid60 was bound to
HmenB3 in a concentration-dependent manner (Fig. 2A), as
for the binding of NMGB PS to HmenB3 (Fig. 2B), and the KD
was 9.2  109 M. However, Naid60 did not bind to HmenB5
(Fig. 2D), which is an isotype-matched anti-NMGB PS MAb
cross-reactive with NCAMs (Fig. 2C). The binding pattern of
E. coli K1 PS to HmenB3 was similar to those of NMGB PS
(data not shown).
Naid60 inhibits the bactericidal activity of HmenB3. To
determine whether Naid60 carries the mimic epitope of
NMGB PS, a bactericidal inhibition assay was performed.
HmenB3 has complement-mediated bactericidal activity
against NMGB, and we measured the bactericidal activity of
HmenB3 against NMGB ATCC 13090 as a representative in
the presence of various concentrations of Naid60 as a compet-
itor to NMGB PS and 10% rabbit complement. When Naid60
was added to concentrations of 4, 40, and 400 g/ml, the
bactericidal inhibitions of HmenB3 by Naid60 were increased
to 36.9%, 92.6%, and 98.0%, respectively. Bactericidal inhibi-
tions by E. coli K1 PS and irrelevant control Ab, positive and
negative control inhibitors, were 38.3% and 12.8% at 40 g/ml,
respectively (Fig. 3). These results indicate that Naid60 con-
tains the peptide mimicry site to NMGB PS and competes for
binding to HmenB3.
Anti-idiotypic scFv. We developed a recombinant anti-idio-
type Ab of a single-chain variable fragment of Naid60 (Naid60-
scFv) for immunization to induce antibodies to NMGB. The
VH and VL regions of Naid60 were cloned using pCANTAB5E
vector, and the scFv gene was excised from the phage clone
showing a positive ELISA signal to HmenB3-coated wells and
then expressed in E. coli BL21 (data not shown). Recombinant
Naid60-scFv was successfully produced with a molecular size of
30 kDa (Fig. 4A), and Naid60-scFv dose-dependently inhib-
ited the binding of HmenB3 to wells coated with NMGB (Fig.
4B) or with whole Naid60 Ab (Fig. 4C), as expected. Naid60-
scFv also inhibited the killing of NMGB by HmenB3 in a
dose-dependent manner (Fig. 4D). These results indicate that
the anti-idiotypic Naid60-scFv also retains the surrogate image
of the carbohydrate epitope for NMGB PS. To determine
whether vaccination with Naid60 can induce anti-NMGB Ab
titers and protect mice from NMGB infection, Naid60-scFv
was used for immunization.
Anti-NMGB Ab production in mice. Next, we further eval-
uated whether the immunization of anti-idiotype Ab could
elicit the production of antibodies against NMGB. First, we
immunized BALB/c mice with Naid60-KLH, which was emul-
sified with CFA, boosted this with IFA three times at 2-week
FIG. 4. Production and characterization of Naid60-scFv. (A) Re-
combinant scFv of Naid60 was produced as described in Materials and
Methods. Affinity-purified Naid60-scFv was run on a 10% sodium
dodecyl sulfate-polyacrylamide gel, and Western blotted using
HmenB3 as a primary antibody after transfer to nitrocellulose, and
identified as a ca. 30-kDa protein. (B and C) Naid60-scFv inhibited the
binding of HmenB3 to wells coated with NMGB bacteria (B) and to
wells coated with Naid60 (C) in a dose-dependent manner.
(D) Naid60-scFv inhibited the complement-mediated bactericidal ac-
tivity of HmenB3 to NMGB bacteria.
FIG. 5. Anti-NMGB Ab levels in Naid60-KLH- or Naid60-scFv-
immunized mice. (A) Groups of five BALB/c mice were injected with
Naid60-KLH, which was emulsified with CFA and IFA, and then
boosted at 2-week intervals. After four injections, mouse sera were
collected and the anti-NMGB Ab titer at a 1:100 dilution was mea-
sured using heat-killed NMGB as a coating antigen. (B) Groups of five
BALB/c mice were injected with Naid60-scFv as described for panel A.
Mouse sera were collected 7 days after each immunization, and the
anti-NMGB Ab titer was measured at a 1:100 dilution. Error bars
indicate standard deviations.
6402 PARK ET AL. INFECT. IMMUN.
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intervals, and obtained serum samples 1 week after every in-
jection. We then measured the anti-NMGB Ab titer according
to boosting injection numbers. Anti-NMGB Ab titers were
significantly elevated as the boosting injections were increased
(Fig. 5). We also observed anti-NMGB Ab production after
immunization with Naid60-scFv or Naid60 F(ab)2-bovine se-
rum albumin into BALB/c mice (data not shown). Anti-NMGB
Ab titers were increased as injection numbers were increased
and sustained a plateau level after the third injection. These
data indicate that Naid60 contains an epitope that can induce
an anti-NMGB antibody response in experimental mice.
Protective efficacy in Naid60-immune mice. To study the
protective efficacy of Naid60, BALB/c mice were immunized
five times with 100 g of Naid60-KLH at 2-week intervals and
then treated with cyclophosphamide to render them suscepti-
ble to meningococcal infections. They were subsequently chal-
lenged with 1  106 CFU of NMGB, and bacterial clearance
was observed. In the KLH-treated control group, detectable
bacteremia was noted in blood at 24 h postinfection, and rapid
bacterial multiplication was observed at days 2 to 4 in three
mice (no. 1, 4, and 5), with signs of weight loss and inactivity,
and then bacterial multiplication declined (Fig. 6A). The other
two mice (no. 2 and 3) showed a little bacteremia on day 4 (Fig.
6A), whereas bacterial multiplication was not observed at 48 h
postinfection in mice immunized with Naid60-KLH and bac-
teria persisted at low levels throughout the course of the ex-
periment (Fig. 6B).
Anti-anti-idiotypic MAb. We produced a monoclonal anti-
anti-idiotypic Ab to confirm the inducibility of protective Ab to
NMGB by Naid60, because some antibodies were reported to
bind to bacteria without promoting bactericidal activity (16,
42) and sera from mice immunized with Naid60 had poor
bactericidal activity. BALB/c mice were immunized with KLH-
conjugated F(ab)2 of Naid60, and MAb MoB34 was produced
by screening the hybridoma supernatants to both NMGB and
FIG. 6. Protective efficacy for Naid60-immune mice. Groups of five
BALB/c mice were subcutaneously immunized with KLH (A) or 100
g of Naid60-KLH (B) with alum and CpG ODN five times at 2-week
intervals and treated with cyclophosphamide to render the mice sus-
ceptible to meningococcal infections. Subsequently the mice were chal-
lenged with 1  106 CFU of NMGB (ATCC 13090). To observe
bacterial clearance, blood specimens were obtained from the retro-
orbital plexus at the indicated times, and 10 l of each blood sample
undiluted or diluted with HBSS at 1:10 or 1:100 was cultured on
chocolate agar plates at 37°C. CFU in duplicate were determined after
18 h of incubation in a candle jar.
FIG. 7. Binding of MoB34 to whole bacterial cells and its bacteri-
cidal activity. (A) MoB34 purified from mouse ascites fluid bound to
NMGB bacteria in dose-dependent manner. (B) The complement-
mediated bactericidal activity of purified MoB34 was observed, and the
50% killing concentration was determined to be 16 ng/ml. (C) The
bactericidal activity of MoB34 was reduced in the presence of Naid60.
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F(ab)2 of Naid60. MoB34 bound to NMGB in a dose-depen-
dent manner, showing an antigen-Ab binding pattern (Fig.
7A), and killed NMGB in the presence of rabbit complement.
The concentration of MoB34 required for 50% killing of
NMGB strain ATCC 13090 was approximately 16 ng/ml (Fig.
7B), and the bactericidal activity of MoB34 was inhibited by
the addition of Naid60 (Fig. 7C) and purified E. coli K1 PS
(data not shown), demonstrating that MoB34 is an anti-anti-
idiotypic MAb and recognizes NMGB PS.
Autoreactivity. It is important that the Ab elicited by immu-
nizing with Naid60 or recombinant Naid60 Ab does not bind to
host cells, because NMGB PS has structural similarity to hu-
man PSA. We determined the possibility of autoreactivity of
MoB34 by using a human neuroblastoma cell line, CHP-134,
which expresses NCAMs decorated with a 50-mer PSA. More
than 90% of the CHP-134 cells used for the study expressed a
marker of NCAMs, CD56 (Fig. 8A). HmenB1, which was pre-
viously shown to bind to CHP-134 cells (42), was used for a
positive control (Fig. 8B). However, MoB34 showed no bind-
ing to CHP-134 cells even at concentrations of or greater than
100 g/ml (Fig. 8A). We tested pooled immune sera from five
mice immunized with Naid60-scFv, and the mouse sera also
showed no binding to CHP-134 cells at 1:10 and 1:50 dilutions
(Fig. 8B). To further delineate the binding of MoB34 to brain
tissue, we examined the binding of MoB34 to frozen sections of
newborn mouse brain. HmenB1 clearly and densely stained
Purkinje cells and neighboring cells in the cerebellum at 0.1
g/ml (Fig. 8C, panel 3). In contrast, MoB34 did not stain the
brain (Fig. 8C, panel 2), with staining comparable to the back-
ground level of irrelevant isotype control Ig (Fig. 8C, panel 1)
at the same concentrations (50 or 100 g/ml), which were
	500 to 1,000-fold higher than the concentration of HmenB1.
Thus, Naid60 has an epitope eliciting anti-NMGB Ab with no
autoreactivity.
DISCUSSION
Our study describes an anti-idiotype antibody, Naid60, that
is capable of mimicking the epitope of NMGB PS and of
producing protective Ab to NMGB. Naid60 could compete the
phage clones containing the peptide mimotope of NMGB PS
(data not shown), which were selectively isolated using
HmenB3 by biopanning a phage peptide library (33, 42).
Naid60-scFv also inhibited the binding and bactericidal activity
of HmenB3 to NMGB, indicating that Naid60 binds to the
idiotope in the antigen-binding groove of HmenB3 and carries
an epitope mimicking NMGB PS.
We produced an anti-anti-idiotypic MAb of MoB34 by using
Naid60 as an immunogen to confirm that Naid60 could induce
a protective Ab to NMGB and to exclude the other possibility
of the involvement of a nonspecific immune reaction in the
protection of Naid60-immune mice. MoB34 bound to NMGB
and showed complement-mediated killing of NMGB in a dose-
dependent manner; moreover, both activities were inhibited by
the addition of Naid60. In our preliminary study, NMGB bac-
teria could not proliferate in neonatal rats when we injected
live bacteria pretreated with MoB34 (data not shown). These
data indicate that Naid60-immune mouse sera contained pro-
tective Ab. A knowledge of the domain of the Naid60 comple-
mentarity-determining region (CDR) responsible for inducing
protective antibody is important. Considering that a synthetic
peptide spanning the VH CDR3 (CDR3H) domain of anti-
idiotypic Ab (48), which mimicked the meningococcal group C
capsular PS, was responsible for inducing protective Ab in
FIG. 8. Autoreactivity tests. (A) Cells were stained with anti-CD56 (green line, left) or isotype control Ab (dotted line). The culture supernatant
of HmenB1 (red line) was bound to PSA on CHP-134 cells (42). One hundred micrograms per ml of MoB34 (green line, right) was used for the
staining. (B) CHP-134 cells were stained with sera from mice immunized with Naid60-scFv. Five mice sera were pooled and used as a primary Ab
at 1:10 (green line, center) and 1:50 (green line, right) dilutions. Preimmune sera (green line, left), the culture supernatant of HmenB1 (red line),
and irrelevant Ab (dotted line) are also shown. (C) A cryosection of neonatal (less than 10-day-old) mouse brain was stained with 50 g/ml of
irrelevant Ab (anti-LPS MAb) (panel 1) and 50 g/ml MoB34 (panel 2). HmenB1 at a concentration of 0.1 g/ml (panel 3) and hematoxylin-eosin
(panel 4) are also shown. Bars, 50 m.
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mice against a live challenge of N. meningitidis group C, we
believe that Naid60 CDR3H is a possible candidate for the
peptide mimicry of NMGB PS. Naid60 CDR3H was sequenced
(data not shown) (GenBank accession no. AY661813), and it
differs from any reported peptide mimotopes of NMGB PS (7,
8, 30, 33, 42). Naid60 CDR3H contained the YXY sequence
motif at the central region, which has been found in peptide
mimics of group B and C meningococci, and the YYYAXDY
sequence motif at the C-terminal end, as for anti-idiotype G1
scFv (3). However, the N-terminal peptide sequence is differ-
ent from that of anti-idiotype G1 scFv.
One novel feature of the present study is the demonstration
of the lack of autoimmunity of both Naid60 immune sera and
the anti-anti-idiotypic MAb, MoB34. The pooled immune sera
of five mice immunized with Naid60-scFv, which contained
anti-NMGB Ab, showed no binding to PSA on CHP-134 cells
(background level). In addition, MoB34 did not bind to CHP-
134 cells by flow cytometry or to the brain tissue of newborn
mice by histochemical staining at a concentration of 100 g/ml,
which is remarkably higher than the physiologic concentration
of total Ab in cerebrospinal fluid (20). These data suggest that
the epitope of Naid60 which induces protective Ab is not
cross-reactive with NCAMs on nerve cells.
The immunogenicity of anti-idiotype antibody is one of the
main issues in regard to vaccine candidates. Our data show that
anti-NMGB Ab could be identified in immune mouse sera
after immunizing with Naid60-KLH, Naid60-scFv, or F(ab)2
of Naid60 and that anti-NMGB Ab titers were boosted with
injection number. We observed growth inhibition of NMGB
bacteria in the blood when we challenged mice immunized
with Naid60-KLH followed by immunosuppression with live
NMGB bacteria, supporting anti-NMGB Ab production in
mice. Unexpectedly, however, the sera from mice immunized
with Naid60 showed no significant bactericidal activity to
NMGB, in contrast to the titer of anti-NMGB Ab by ELISA,
even though the immunized mice were protected from the live
NMGB challenge. The reason for this is unknown, but this
phenomenon could be observed in mouse immune sera of
anti-idiotype G1 scFv (3) to Seam 3, which is a protective MAb
raised against a chemically modified form of N-propionyl me-
ningococcal B PS (16). Our study of protective efficacy in
Naid60-immune mice is preliminary, and further evaluation
using a more established infant rat or mouse model system is
necessary.
The feasibility of using a peptide mimotope as a surrogate
for the nominal antigen is important in vaccine approaches.
Maitta et al. (27) reported that the peptide mimotope of Cryp-
tococcus neoformans capsular PS glucuronoxylomannan can
elicit an Ab response to glucuronoxylomannan in mice trans-
genic for the human Ig loci (XenoMouse mice), thus support-
ing the concept that peptide mimotope-based vaccines are
likely. However, one main limitation in our study is the weak
immunogenicity of anti-idiotype Ab, which was found in an-
other study (3). To increase immunogenicity, multiepitope
DNA vaccines encoding a T-cell helper epitope and a target
molecule of one or more peptide epitopes in tandem have been
tried, and functional antibodies have been generated in studies
of a viral epitope (25), a carbohydrate mimotope of group C
meningococcus (38) and the neogalactoseries Lewis Y antigen
with interleukin-12 (23). Chambers and Johnston (6) showed
another efficient method of genetic immunization, with con-
structs containing the T-cell epitope and the cartilage oli-
gomerization matrix protein for pentameric formation of an-
tigen (44) in the presence of genetic adjuvants of Flt3L and
granulocyte-macrophage colony-stimulating factor in mice.
Considering that plasmid constructs containing genomic DNA
or synthetic DNA from 42 to 60 bp could efficiently induce Ab
production (6), the anti-idiotope of Naid60 may be a candidate
for further study.
In conclusion, a non-cross-reactive and protective epitope is
located on NMGB PS, and an anti-idiotype vaccine to this
epitope may be a useful NMGB vaccine.
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